Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea

Tehran University of Medical Sciences250 enrolled

Overview

This study has been designed to investigate the comparative effects of sitagliptin vs. pioglitazone as add-on treatments in patients with type 2 diabetes who were uncontrolled on the full-dose of metformin and sulfonylurea

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

250

Conditions

Uncontrolled Type 2 Diabetes Mellitus

Interventions

Sitagliptin 100mgDRUG

Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks

Pioglitazone 30 mgDRUG

Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks

Eligibility

Sex: ALLMin age: 25 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of type 2 diabetes according to the American Diabetes Association * Baseline level of 7% ≤ A1C \< 11% despite a minimum 6 months period of active treatment with metformin 2000 mg/day plus gliclazide 240 mg/day (uncontrolled type 2 diabetes) Exclusion Criteria: * Acute or chronic diseases of heart, lung, kidney, * Active or past infectious conditions * Malignancy

Locations (1)

Tehran University of Medical Sciences

Tehran, Iran

Outcomes

Primary Outcomes

Change from baseline in mean glycated hemoglobin (A1C) levels by sitagliptin vs. pioglitazone

Time frame: 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.